Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tafamidis meglumine - Pfizer

Next Previous
Drug Profile

Tafamidis meglumine - Pfizer

Alternative Names: Fx-1006A; FX1006A; PF-06291826; PF-6291826; Tafamidis; Tafamidis free acid; VYNDAMAX; Vyndaqel; Vynmac

Latest Information Update: 01 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FoldRx Pharmaceuticals
  • Developer Pfizer
  • Class Benzoxazoles; Carboxylic acids; Cardiovascular therapies; Chlorobenzenes; Neuroprotectants; Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies; Amyloid polyneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy; Cardiomyopathies

Most Recent Events

  • 29 Aug 2025 Updated efficacy data from ATTR-ACT trial in Cardiomyopathy presented at the Annual Congress of the European Society of Cardiology together with World Congress of Cardiology (ESC-Card-WCC-2025)
  • 04 Apr 2025 Pfizer completes phase I bioavailability trial (In volunteers) in Belgium (PO, Tablet) (NCT06705569)
  • 28 Feb 2025 No recent reports of development identified for phase-I development in Amyloid polyneuropathy(In volunteers) in Belgium (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top